Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.03 -0.74 (-0.50%)
Official Closing Price Updated: 7:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,773,083
Open 147.44
Bid (Size) 147.03 (23)
Ask (Size) 148.31 (1)
Prev. Close 147.77
Today's Range 146.61 - 148.38
52wk Range 140.68 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
Exposures Fossil Fuels Interest Rates

Performance

YTD
+2.09%
+2.09%
1 Month
+2.28%
+2.28%
3 Month
-9.70%
-9.70%
6 Month
-4.67%
-4.67%
1 Year
-9.06%
-9.06%

More News

Read More
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
Via The Motley Fool
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy in 2025
Via The Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Via Benzinga
Topics Government
Exposures Political
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Via MarketBeat
Exposures Product Safety
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
10 One Decision Stocks To Buy Now
Via Talk Markets
Topics Stocks / Equities
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
Via Benzinga
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Via Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
Via Investor's Business Daily
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
Via Stocktwits
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
A Look At Dividend Kings
Via Talk Markets
Topics ETFs Stocks / Equities
Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
Via The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.